13.56

2.73% +0.36

After Hours: 13.5679 0.0079 +0.06%

HilleVax Inc (HLVX)

Overview News Price History Discussions Forecast

HilleVax Inc stock is currently priced at $13.56, with a 24-hour trading volume of 107.57K. It has seen a +2.73% increased in the last 24 hours and a -14.88% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $13.32 pivot point. If it approaches the $13.61 resistance level, significant changes may occur.

Previous Close:

$13.20

Open:

$13.28

24h Volume:

107.57K

Market Cap:

$674.22M

Revenue:

Net Income/Loss:

$-123.57M

P/E Ratio:

-5.5122

EPS:

-2.46

Net Cash Flow:

$-97.53M

1W Performance:

+7.79%

1M Performance:

-14.88%

6M Performance:

+13.95%

1Y Performance:

+0.00%

1D Range:

$13.20

$14.17

52W Range:

$9.94

$20.22

HilleVax Inc Stock (HLVX) Company Profile

Name

HilleVax Inc

Sector

Healthcare (1189)

Industry

Biotechnology (685)

Phone

617 213 5054

Address

75 State Street, Suite 100- #9995, Boston

Employee

Twitter

Next Earnings Date

Latest SEC Filings

HLVX's Discussions on Twitter

HilleVax Inc Stock (HLVX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-13-23	Initiated	H.C. Wainwright	Buy

HilleVax Inc Stock (HLVX) Latest News

HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress

GlobeNewswire Inc.

HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference

GlobeNewswire Inc.

HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

GlobeNewswire Inc.

HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc.

HilleVax, Inc. (HLVX) Moves to Buy: Rationale Behind the Upgrade

Zacks Investment Research

Does HilleVax, Inc. (HLVX) Have the Potential to Rally 107.23% as Wall Street Analysts Expect?

Zacks Investment Research

HilleVax Inc Stock (HLVX) Financials Data

HilleVax Inc (HLVX) Net Income 2024

HLVX net income (TTM) was -$123.57 million for the quarter ending December 31, 2023, a +22.68% increase year-over-year.

HilleVax Inc (HLVX) Cash Flow 2024

HLVX recorded a free cash flow (TTM) of -$97.53 million for the quarter ending December 31, 2023, a -42.37% decrease year-over-year.

HilleVax Inc (HLVX) Earnings per Share 2024

HLVX earnings per share (TTM) was -$3.04 for the quarter ending December 31, 2023, a +42.52% growth year-over-year.

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.